Review Article
Autoantibodies in autoimmune liver diseases
Asli Gamze Sener,
Corresponding Author
Asli Gamze Sener
Medical Microbiology Department, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
Asli Gamze Sener, Medical Microbiology Department, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir 35170, Turkey. e-mail: [email protected]Search for more papers by this authorAsli Gamze Sener,
Corresponding Author
Asli Gamze Sener
Medical Microbiology Department, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
Asli Gamze Sener, Medical Microbiology Department, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir 35170, Turkey. e-mail: [email protected]Search for more papers by this authorAbstract
Autoimmune hepatitis is a chronic hepatitis of unknown etiology characterized by clinical, histological, and immunological features, generally including circulating autoantibodies and a high total serum and/or gamma globulin. Liver-related autoantibodies are very significant for the correct diagnosis and classification of autoimmune liver diseases (AILD), namely autoimmune hepatitis types 1 and 2 (AIH-1 and 2), primary biliary cirrhosis (PBC), and the sclerosing cholangitis types in adults and children. This article intends to review recent studies that investigate autoantibodies in autoimmune liver diseases from a microbiological perspective.
References
- 1Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193–213.
- 2Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008; 14: 3374–87.
- 3Krawitt EL. Discrimination of autoimmune hepatitis: autoantibody typing and beyond. J Gastroenterol 2011; 46(Suppl 1): 39–41.
- 4Krawitt EL. Clinical features and management of autoimmune hepatitis. World J Gastroenterol 2008; 14: 3301–5.
- 5Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354: 54–66.
- 6Bogdanos DP, Mieli-Vergani G, Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis 2009; 29: 241–53.
- 7Oo YH, Hubscher SG, Adams DH. Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol Int 2010; 4: 475–93.
- 8Zachou K, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis 2004; 1: 2.
- 9Johanet C, Beleoken E, Ballot E. Autoantibodies in autoimmune hepatitis: antinuclear antibodies (ANA). Clin Res Hepatol Gastroenterol 2012; 36: 394–6.
- 10Liberal R, Grant CR, Longhi MS, Mieli-Vergani G, Vergani D. Diagnostic criteria of autoimmune hepatitis. Autoimmun Rev 2014; 13: 435–40.
- 11Zhang WC, Zhao FR, Chen J, Chen WX. Meta-analysis: diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a soluble liver antigen/liver pancreas in autoimmune hepatitis. PLoS One 2014; 9: e92267. doi:10.1371/journal.pone.0092267.
- 12Johanet C, Ballot E. Auto-antibodies in autoimmune hepatitis: anti-smooth muscle antibodies (ASMA). Clin Res Hepatol Gastroenterol 2012; 36: 189–91.
- 13Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1: 292–4.
- 14Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 1993; 18: 1–9.
- 15Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado EL, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002; 51: 259–64.
- 16Meda F, Zuin M, Invernizzi P, Vergani D, Selmi C. Serum autoantibodies: a road map for the clinical hepatologist. Autoimmunity 2008; 41: 27–34.
- 17Hu CJ, Zhang FC, Li YZ, Zhang X. Primary biliary cirrhosis: what do autoantibodies tell us? World J Gastroenterol 2010; 16: 3616–29.
- 18Bridoux-Henno L, Maggiore G, Johanet C, Fabre M, Vajro P, Dommergues J-P, et al. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004; 2: 825–30.
- 19Liberal R, Mieli-Vergani G, Vergani D. Clinical significance of autoantibodies in autoimmune hepatitis. J Autoimmun 2013; 46: 17–24.
- 20Vergani D, Alvarez F, Bianchi FB, Cancado EL, Mackay IR, Manns MP, et al. International Autoimmune Hepatitis Group. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41: 677–83.
- 21Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001; 21: 225–32.
- 22Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169–76.
- 23Vierling JM. Diagnosis and treatment of autoimmune hepatitis. Curr Gastroenterol Rep 2012; 14: 25–36.
- 24Beland K, Lapierre P, Marceau G, Alvarez F. Anti-LC autoantibodies in patients with chronic hepatitis C virus infection. J Autoimmun 2004; 22: 159–66.
- 25Rigopoulou EI, Mytilinaiou M, Romanidou O, Liaskos C, Dalekos GN. Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. J Autoimmune Dis 2007; 4: 2.
- 26Gatselis NK, Zachou K, Koukoulis GK, Dalekos GN. Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. World J Gastroenterol 2015; 21: 60–83.
- 27Zachou K, Muratori P, Koukoulis GK, Granito A, Gatselis N, Fabbri A, et al. Review article: autoimmune hepatitis – current management and challenges. Aliment Pharmacol Ther 2013; 38: 887–913.
- 28Makaritsis KP, Gatselis NK, Ioannou M, Petinaki E, Dalekos GN. Polyclonal hypergammaglobulinemia and high smooth-muscle autoantibody titers with specificity against filamentous actin: consider visceral leishmaniasis, not just autoimmune hepatitis. Int J Infect Dis 2009; 13: e157–60.
- 29McFarlane IG, Wojcicka BM, Zucker GM, Eddleston AL, Williams R. Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol 1977; 27: 381–90.
- 30Rigopoulou EI, Roggenbuck D, Smyk DS, Liaskos C, Mytilinaiou MG, Feist E, et al. Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: lost and found. Autoimmun Rev 2012; 12: 260–9.
- 31Strassburg CP, Manns MP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis 2002; 22: 339e52.
- 32Treichel U, Gerken G, Rossol S, Rotthauwe HW, Meyer zum Buschenfelde KH, et al. Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis. J Hepatol 1993; 19: 55–63.
- 33Dalekos GN, Zachou K, Liaskos C, Gatselis N. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med 2002; 13: 293–303.
- 34Vergani D, Longhi MS, Bogdanos DP, Ma Y, Mieli-Vergani G. Autoimmune hepatitis. Semin Immunopathol 2009; 31: 421e35.
- 35Lata J. Diagnosis and treatment of autoimmune hepatitis. Dig Dis 2012; 30: 212–5.
- 36Moy L, Levine J. Autoimmune hepatitis: a classic autoimmune liver disease. Curr Probl Pediatr Adolesc Health Care 2014; 44: 341–6.
- 37Meroni PL, Bizzaro N, Cavazzana I, Borghi MO, Tincani A. Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations. BMC Med 2014; 12: 38.
- 38Couto CA, Bittencourt PL, Porta G, Abrantes-Lemos CP, Carrilho FJ, Guardia BD, et al. Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis. Hepatology 2014; 59: 592–600.
- 39Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997; 26: 561–6.
- 40Radzimski C, Probst C, Teegen B, Rentzsch K, Blöcker IM, Dähnrich C, et al. Development of a recombinant cell-based indirect immunofluorescence assay for the determination of autoantibodies against soluble liver antigen in autoimmune hepatitis. Clin Dev Immunol 2013; 2013: 572815. doi:10.1155/2013/572815.
